611 reports of this reaction
3.0% of all TOBRAMYCIN SULFATE reports
#6 most reported adverse reaction
INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS is the #6 most commonly reported adverse reaction for TOBRAMYCIN SULFATE, manufactured by Fresenius Kabi USA, LLC. There are 611 FDA adverse event reports linking TOBRAMYCIN SULFATE to INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS. This represents approximately 3.0% of all 20,334 adverse event reports for this drug.
Patients taking TOBRAMYCIN SULFATE who experience infective pulmonary exacerbation of cystic fibrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS is a less commonly reported adverse event for TOBRAMYCIN SULFATE, but still significant enough to appear in the safety profile.
In addition to infective pulmonary exacerbation of cystic fibrosis, the following adverse reactions have been reported for TOBRAMYCIN SULFATE:
The following drugs have also been linked to infective pulmonary exacerbation of cystic fibrosis in FDA adverse event reports:
INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS has been reported as an adverse event in 611 FDA reports for TOBRAMYCIN SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS accounts for approximately 3.0% of all adverse event reports for TOBRAMYCIN SULFATE, making it a notable side effect.
If you experience infective pulmonary exacerbation of cystic fibrosis while taking TOBRAMYCIN SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.